Gonadorelin: Uses and Dosing Protocol

What Is Gonadorelin?

Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH). GnRH is produced by the hypothalamus and travels to the anterior pituitary gland, where it stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones are essential for reproductive function in both men and women.

The clinical importance of gonadorelin has grown significantly since 2020, when HCG (human chorionic gonadotropin) was removed from compounding pharmacy availability in the United States following FDA reclassification. Gonadorelin has emerged as the primary alternative for maintaining testicular function and fertility during testosterone replacement therapy.

Mechanism of Action

Gonadorelin's effects depend critically on its administration pattern. Pulsatile administration (small doses every 60-120 minutes, or intermittent bolus injections) stimulates LH and FSH release. This mimics the natural pulsatile release of GnRH from the hypothalamus and maintains normal gonadotropin production. Continuous administration, in contrast, actually suppresses LH and FSH through receptor desensitization and downregulation -- this is the principle behind GnRH agonist medications used in prostate cancer and endometriosis.

For peptide research purposes, the intermittent bolus injection approach (2-3 times per week) falls into the stimulatory pattern, supporting gonadotropin release.

Clinical Uses

TRT Fertility Preservation

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback, dramatically reducing LH and FSH levels. This leads to testicular atrophy and severely impaired spermatogenesis, which can result in infertility. Gonadorelin maintains pituitary LH/FSH output, preserving testicular volume and spermatogenesis even while on TRT. Common protocols use 100-200 mcg subcutaneously 2-3 times per week alongside testosterone.

Post-Cycle Therapy (PCT)

After discontinuing exogenous hormones, the HPG axis may take weeks to months to recover normal function. Gonadorelin can accelerate this recovery by directly stimulating the pituitary to resume LH/FSH production, serving as a bridge therapy to help restore endogenous testosterone.

Diagnostic Testing

Gonadorelin is used diagnostically to assess pituitary function. A bolus injection followed by serial LH/FSH measurements helps differentiate between hypothalamic and pituitary causes of hypogonadism. A normal LH/FSH response to gonadorelin suggests the pituitary is functional and the issue lies upstream at the hypothalamic level.

Dosing Protocols

TRT Support Protocol

• Dose: 100-200 mcg per injection
• Frequency: 2-3 times per week
• Route: Subcutaneous injection
• Duration: Ongoing while on TRT

PCT Protocol

• Dose: 100-200 mcg per injection
• Frequency: Daily or every other day for 2-4 weeks
• Often combined with SERMs (clomiphene, enclomiphene)

Peptide Calculator Setup

Gonadorelin commonly comes in 2 mg vials. Using the Peptide Calculator Plus:

• 2 mg vial + 2 mL BAC water = 1,000 mcg/mL
• For 100 mcg: draw 10 units on a U-100 syringe
• For 200 mcg: draw 20 units on a U-100 syringe

Gonadorelin vs HCG

Understanding the differences between gonadorelin and HCG is important for protocol design. HCG mimics LH directly at the testicular level, bypassing the pituitary, and has a long half-life (24-36 hours), allowing for 2-3x per week dosing. Gonadorelin stimulates natural LH/FSH release from the pituitary, preserving the full HPG axis, but has a very short half-life (minutes), requiring more frequent dosing for continuous effect. Both maintain testicular volume and spermatogenesis during TRT, though HCG has more published data for this application.

Side Effects and Safety

Gonadorelin is generally well-tolerated with minimal side effects at standard doses. Reported effects include injection site discomfort, occasional headache, mild flushing after injection, and transient nausea. The main risk is related to overdosing or continuous (non-pulsatile) administration, which paradoxically suppresses the HPG axis. Maintaining the intermittent dosing schedule is essential for stimulatory effects.